Clinical trials: Tumor Patients
Barrett's Esophagus
Detection of Barrett s Esophagus in Patients Without GERD Symptoms
The purpose of this study is to develop a method to detect Barrett's esophagus (BE) in individuals with a new office-based diagnostic test.
- Trial name
- NCT04880044
- Testing
- EsoCheck/EsoGuard (EC/EG), Esophago-gastro-duodenoscopy (EGD)
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Case Comprehensive Cancer Center
Estrogen Receptor Negative, HER2/Neu Negative
RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) when given together with vismodegib in treating patients with breast cancer that is metastatic…
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma
- Trial name
- NCT01071564
- Testing
- Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacogenomic Study
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Colon Cancer
DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease
To learn if lifestyle changes (such as diet and exercise) combined with daily aspirin and vitamin D can affect the likelihood of advanced colorectal cancer coming back (recurring)
- Trial name
- NCT05036109
- Testing
- Aspirin, Vitamin D, Diet
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Soft Tissue Sarcoma
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure
The purpose of this study is to assess efficacy and safety of LBH589 - Panobinostat®, a potent HDACi, in patients with advanced STS who experiment disease progression after or during first-line chemotherapy.
- Trial name
- ESTIM-LBH (NCT01136499)
- Testing
- LBH589 (Panobinostat®)
- Where
- France
- Volunteers
- 53 people
- Sponsor
- Centre Leon Berard
HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer
Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors
Phase I Dose Finding Study for GQ1001 in Patients with HER2-Positive Advanced Solid Tumors
- Conditions
- HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor
- Trial name
- NCT04450732
- Testing
- GQ1001
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 96 people
- Sponsor
- GeneQuantum Healthcare (Suzhou) Co., Ltd.
Leukemia, Myelodysplastic Syndromes
Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
RATIONALE: Doxercalciferol may improve low blood cell counts and decrease the need for blood transfusions and may be an effective treatment for myelodysplastic syndrome or chronic myelomonocytic leukemia.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00052832
- Testing
- doxercalciferol
- Where
- United States
- Sponsor
- University of Wisconsin, Madison
Biliary Tract Cancer
A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy
To decide maximum tolerated dose and recommended dose of treatment using gemcitabine plus cisplatin combination therapy in patients with biliary tract cancer undergoing resection without major hepatectomy.
- Trial name
- NCT01297998
- Testing
- gemcitabine , cisplatin
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- Kansai Hepatobiliary Oncology Group
Advanced Solid Tumors
A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors
This is a Phase 1, open-label, dose-escalation and cohort expansion study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of IMM2510(Anti-PD-L1 and VEGF trap recombinant…
- Trial name
- NCT07170787
- Testing
- IMM2510, IMM01
- Where
- China
- Volunteers
- 104 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Symptoms and Signs Involving Cognition Perception Emotion & Behaviour, Abdominal Cancer Patients
Investigating the Effect of Simulated Live Piano Music on Preoperative Cancer Patients, Health Care Providers and Hospital Volunteers Using Validated Questionnaires and Proteomic Analysis
The goal of this research study is to learn if simulated live piano music can change the amount of stress felt in patients with cancer before surgery, health care providers caring for cancer patients, and/or hospital volunteers.
- Trial name
- NCT03239587
- Testing
- Musical Intervention, Blood Draws, Questionnaires
- Sponsor
- M.D. Anderson Cancer Center
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
This phase I/II trial studies the side effects and best dose of cabazitaxel when given together with enzalutamide in treating patients with prostate cancer that has spread to other places in the body (metastatic) and has not…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
- Trial name
- NCT02522715
- Testing
- Cabazitaxel, Enzalutamide, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- OHSU Knight Cancer Institute
Chronic Myeloid Leukemia
Leukemic Stem Cell Detection for Chronic Myeloid Leukemia Patients With Major Molecular Response
Multi-Center, national, non-drug, prospective cohort study Target patient number is 100 The amount of CD45+/CD34+/CD38-/CD26+ levels of chronic myeloid leukemia (CML) stem cells in CML patients with and without BCR-ABL…
- Trial name
- NCT04104035
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Ankara University
Non-Small Cell Lung Cancer
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
The purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or increased MET or AXL activity.
- Trial name
- NCT01639508
- Testing
- Cabozantinib
- Where
- 7 sites in United States
- Volunteers
- 86 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma, Non-Hodgkins Lymphoma
Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection
The purpose of this study is to determine whether it is safe and effective to collect peripheral blood hematopoietic stem cells 16 hours rather than the usual 11 hours after administration of plerixafor.
- Trial name
- NCT01042717
- Testing
- Plerixafor
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Shi, Patricia, M.D.
Geriatric Cancer Patients
A Chatbot-Powered G8 Screening Intervention to Facilitate Referrals to a Comprehensive Geriatric Assessment Among Older Adults With Cancer
In this prospective quality improvement study, we will develop and evaluate the feasibility and acceptability of an online patient self-reported G8 screening tool which will allow us to efficiently identify G8 positive older…
- Trial name
- NCT05535140
- Testing
- G8 Screening Tool
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Thomas Jefferson University
Advanced Solid Tumors
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
The proposed clinical trial is a phase I, open-label, multi-center, dose-escalation study of ALT-803 in patients with surgically incurable advanced solid tumors: melanoma, renal cell, non-small cell lung and squamous cell head…
- Trial name
- NCT01946789
- Testing
- ALT-803
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
This clinical trial was done to show whether a radioactive drug (I-131-1095) that binds to prostate-specific membrane antigen (PSMA) is useful in treating metastatic prostate cancer that is positive for PSMA.
- Conditions
- Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm, Cancer of the Prostate
- Trial name
- ARROW (NCT03939689)
- Testing
- I-131-1095, Enzalutamide
- Where
- 27 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Chronic Pain Syndrome, Sensitization, Central
Management of Chronic Non-Cancer Pain With Non-Pharmacological Therapies
A randomized controlled clinical trial will be conducted, involving a psychoeducational activity as the intervention. There will be a control group of patients with non-cancer chronic pain who will continue their usual treatment.
- Conditions
- Chronic Pain Syndrome, Sensitization, Central, Quality of Life, Patient Empowerment
- Trial name
- NCT06440668
- Testing
- Chronic Pain Management Workshop with Non-Pharmacological Therapies
- Where
- Spain
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Hospital San Juan de Dios del Aljarafe de Sevilla
All Tumor Entities Treated With TKI Therapy
Reduction of Cancer Related Fatigue in Patients During TKI Therapy
The purpose of this pilot study is to determine the effects of a 12-week resistance training program on cancer related fatigue in cancer patients receiving tyrosine kinase inhibitor (TKI) therapy.
- Trial name
- RECAP (NCT01645150)
- Testing
- Progressive strength training
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- German Cancer Research Center
Ovarian Cancer, Peritoneal Cavity Cancer
Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer
RATIONALE: Inserting the p53 gene into a person's cancer cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy.
- Trial name
- NCT00003450
- Testing
- Ad5CMV-p53 gene
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
NSCLC Stage IV, Limited Metastatic Disease
Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR)
This will be a phase II trial testing if the combination of SBRT and L19-IL2 improves the progression free survival in patients with limited metastatic non-small cell lung cancer (NSCLC).
- Trial name
- ImmunoSABR (NCT02735850)
- Testing
- L19-IL2, SBRT, No intervention
- Where
- Netherlands
- Sponsor
- Maastricht Radiation Oncology